{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T09:44:30Z","timestamp":1771062270991,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T00:00:00Z","timestamp":1620777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T00:00:00Z","timestamp":1620777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Gemcitabine and cisplatin are chemotherapeutic agents used for treating multiple cancers, and these agents are sometimes used in combination. Drug-induced thrombotic microangiopathy (TMA) is a rare but potentially fatal complication. It typically presents as a systemic disease with the classical triad of hemolytic anemia, thrombocytopenia, and organ damage. In contrast to systemic TMA, cases of renal-limited TMA, defined as biopsy-proven renal TMA without the classical triad, have been reported with relatively good prognosis. Most cases of renal-limited TMA are associated with calcineurin inhibitors, and cases of drug-induced renal-limited TMA due to gemcitabine-dexamethasone-cisplatin therapy have been rarely reported.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>A 43-year-old woman with lymphoma developed acute kidney injury with marked proteinuria, microhematuria, and abnormal urinary casts after receiving one cycle of gemcitabine-dexamethasone-cisplatin therapy. Although she did not show hemolytic anemia and thrombocytopenia, renal biopsy showed diffuse injury to the glomerular endothelial cells, supporting the diagnosis of renal-limited TMA. Her condition improved only with the cessation of gemcitabine and cisplatin treatment. She received another chemotherapy without gemcitabine and platinum agents, and no recurrence of renal-limited TMA was observed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Drug-induced TMA occurs early after gemcitabine and cisplatin use in renal-limited form and is reversible when detected and managed in a timely manner. Urinalysis, which is simple and inexpensive and can be easily performed, is a beneficial screening tool for early-onset drug-induced TMA among patients who receive gemcitabine-dexamethasone-cisplatin therapy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12882-021-02386-y","type":"journal-article","created":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T07:08:03Z","timestamp":1620803283000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Reversible renal-limited thrombotic microangiopathy due to gemcitabine-dexamethasone-cisplatin therapy: a case report"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6183-8910","authenticated-orcid":false,"given":"Masashi","family":"Nishikubo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshimitsu","family":"Shimomura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiro","family":"Hiramoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naohiko","family":"Sawamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takako","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeo","family":"Hara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,12]]},"reference":[{"issue":"4","key":"2386_CR1","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1182\/blood-2014-11-611335","volume":"125","author":"ZL Al-Nouri","year":"2015","unstructured":"Al-Nouri ZL, Reese JA, Terrell DR, Vesely SK, George JN. Drug-induced thrombotic microangiopathy: a systematic review of published reports. Blood. 2015;125(4):616\u20138. https:\/\/doi.org\/10.1182\/blood-2014-11-611335.","journal-title":"Blood."},{"issue":"21","key":"2386_CR2","doi-asserted-by":"publisher","first-page":"3543","DOI":"10.1200\/JCO.2007.15.0375","volume":"26","author":"GV Scagliotti","year":"2008","unstructured":"Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26(21):3543\u201351. https:\/\/doi.org\/10.1200\/JCO.2007.15.0375.","journal-title":"J Clin Oncol"},{"issue":"14","key":"2386_CR3","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273\u201381. https:\/\/doi.org\/10.1056\/NEJMoa0908721.","journal-title":"N Engl J Med"},{"issue":"24","key":"2386_CR4","doi-asserted-by":"publisher","first-page":"3946","DOI":"10.1200\/JCO.2005.05.1490","volume":"24","author":"V Heinemann","year":"2006","unstructured":"Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Sch\u00f6nek\u00e4s H, Rost A, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol. 2006;24(24):3946\u201352. https:\/\/doi.org\/10.1200\/JCO.2005.05.1490.","journal-title":"J Clin Oncol"},{"issue":"10","key":"2386_CR5","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1200\/JCO.2011.38.6979","volume":"30","author":"J Bellmunt","year":"2012","unstructured":"Bellmunt J, von der Maase H, Mead GM, Skoneczna I, De Santis M, Daugaard G, et al. Randomized phase III study comparing paclitaxel\/cisplatin\/gemcitabine and gemcitabine\/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC intergroup study 30987. J Clin Oncol. 2012;30(10):1107\u201313. https:\/\/doi.org\/10.1200\/JCO.2011.38.6979.","journal-title":"J Clin Oncol"},{"issue":"8","key":"2386_CR6","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1002\/cncr.20587","volume":"101","author":"M Crump","year":"2004","unstructured":"Crump M, Baetz T, Couban S, Belch A, Marcellus D, Howson-Jan K, et al. Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a phase II study by the National Cancer Institute of Canada clinical trials group (NCIC-CTG). Cancer. 2004;101(8):1835\u201342. https:\/\/doi.org\/10.1002\/cncr.20587.","journal-title":"Cancer."},{"issue":"31","key":"2386_CR7","doi-asserted-by":"publisher","first-page":"3490","DOI":"10.1200\/JCO.2013.53.9593","volume":"32","author":"M Crump","year":"2014","unstructured":"Crump M, Kuruvilla J, Couban S, MacDonald DA, Kukreti V, Kouroukis CT, et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J Clin Oncol. 2014;32(31):3490\u20136. https:\/\/doi.org\/10.1200\/JCO.2013.53.9593.","journal-title":"J Clin Oncol"},{"issue":"8","key":"2386_CR8","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1097\/00001813-200309000-00014","volume":"14","author":"G Rabinowits","year":"2003","unstructured":"Rabinowits G, Herchenhorn D, Rabinowits M, Weatge D, Torres W. Fatal pulmonary toxicity in a patient treated with gefitinib for non-small cell lung cancer after previous hemolytic-uremic syndrome due to gemcitabine. Anti-Cancer Drugs. 2003;14(8):665\u20138. https:\/\/doi.org\/10.1097\/00001813-200309000-00014.","journal-title":"Anti-Cancer Drugs"},{"issue":"4","key":"2386_CR9","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1093\/ckj\/sft065","volume":"6","author":"RD Gilbert","year":"2013","unstructured":"Gilbert RD, Stanley LK, Fowler DJ, Angus EM, Hardy SA, Goodship TH. Cisplatin-induced haemolytic uraemic syndrome associated with a novel intronic mutation of CD46 treated with eculizumab. Clin Kidney J. 2013;6(4):421\u20135. https:\/\/doi.org\/10.1093\/ckj\/sft065.","journal-title":"Clin Kidney J"},{"issue":"7","key":"2386_CR10","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/S1470-2045(07)70203-6","volume":"8","author":"M Zupancic","year":"2007","unstructured":"Zupancic M, Shah PC, Shah-Khan F. Gemcitabine-associated thrombotic thrombocytopenic purpura. Lancet Oncol. 2007;8(7):634\u201341. https:\/\/doi.org\/10.1016\/S1470-2045(07)70203-6.","journal-title":"Lancet Oncol"},{"issue":"1","key":"2386_CR11","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40620-017-0392-z","volume":"31","author":"S Manohar","year":"2018","unstructured":"Manohar S, Leung N. Cisplatin nephrotoxicity: a review of the literature. J Nephrol. 2018;31(1):15\u201325. https:\/\/doi.org\/10.1007\/s40620-017-0392-z.","journal-title":"J Nephrol"},{"issue":"2","key":"2386_CR12","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/bcp.13808","volume":"85","author":"F Daviet","year":"2019","unstructured":"Daviet F, Rouby F, Poullin P, Moussi-Franc\u00e8s J, Sall\u00e9e M, Burtey S, et al. Thrombotic microangiopathy associated with gemcitabine use: presentation and outcome in a national French retrospective cohort. Br J Clin Pharmacol. 2019;85(2):403\u201312. https:\/\/doi.org\/10.1111\/bcp.13808.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"2386_CR13","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1080\/028418698423267","volume":"37","author":"M van der Heijden","year":"1998","unstructured":"van der Heijden M, Ackland SP, Deveridge S. Haemolytic uraemic syndrome associated with bleomycin, epirubicin and cisplatin chemotherapy--a case report and review of the literature. Acta Oncol. 1998;37(1):107\u20139. https:\/\/doi.org\/10.1080\/028418698423267.","journal-title":"Acta Oncol"},{"issue":"2","key":"2386_CR14","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1093\/annonc\/mdl395","volume":"18","author":"F Morschhauser","year":"2007","unstructured":"Morschhauser F, Depil S, Jourdan E, Wetterwald M, Bouabdallah R, Marit G, et al. Phase II study of gemcitabine-dexamethasone with or without cisplatin in relapsed or refractory mantle cell lymphoma. Ann Oncol. 2007;18(2):370\u20135. https:\/\/doi.org\/10.1093\/annonc\/mdl395.","journal-title":"Ann Oncol"},{"issue":"2","key":"2386_CR15","doi-asserted-by":"publisher","first-page":"300","DOI":"10.2215\/CJN.00620117","volume":"13","author":"V Brocklebank","year":"2018","unstructured":"Brocklebank V, Wood KM, Kavanagh D. Thrombotic microangiopathy and the kidney. Clin J Am Soc Nephrol. 2018;13(2):300\u201317. https:\/\/doi.org\/10.2215\/CJN.00620117.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"2386_CR16","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1053\/ajkd.2003.50058","volume":"41","author":"J Schwimmer","year":"2003","unstructured":"Schwimmer J, Nadasdy TA, Spitalnik PF, Kaplan KL, Zand MS. De novo thrombotic microangiopathy in renal transplant recipients: a comparison of hemolytic uremic syndrome with localized renal thrombotic microangiopathy. Am J Kidney Dis. 2003;41(2):471\u20139. https:\/\/doi.org\/10.1053\/ajkd.2003.50058.","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"2386_CR17","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1046\/j.1523-1755.1999.00492.x","volume":"55","author":"A Zarifian","year":"1999","unstructured":"Zarifian A, Meleg-Smith S, O'donovan R, Tesi RJ, Batuman V. Cyclosporine-associated thrombotic microangiopathy in renal allografts. Kidney Int. 1999;55(6):2457\u201366. https:\/\/doi.org\/10.1046\/j.1523-1755.1999.00492.x.","journal-title":"Kidney Int"},{"issue":"1","key":"2386_CR18","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12882-018-1194-9","volume":"20","author":"R Yamada","year":"2019","unstructured":"Yamada R, Okawa T, Matsuo K, Suzuki M, Mori N, Mori K. Renal-limited thrombotic microangiopathy after switching from bevacizumab to ramucirumab: a case report. BMC Nephrol. 2019;20(1):14. https:\/\/doi.org\/10.1186\/s12882-018-1194-9.","journal-title":"BMC Nephrol"},{"issue":"3","key":"2386_CR19","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1093\/ckj\/sfu035","volume":"7","author":"J Anjelo","year":"2014","unstructured":"Anjelo J, Rao N, David VG, Otto S, Russ G. Renal-limited thrombotic microangiopathy and acute interstitial nephritis with a single dose of quinine. Clin Kidney J. 2014;7(3):311\u20133. https:\/\/doi.org\/10.1093\/ckj\/sfu035.","journal-title":"Clin Kidney J"},{"issue":"3","key":"2386_CR20","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1097\/00001813-199803000-00001","volume":"9","author":"MS Aapro","year":"1998","unstructured":"Aapro MS, Martin C, Hatty S. Gemcitabine--a safety review. Anti-Cancer Drugs. 1998;9(3):191\u2013201. https:\/\/doi.org\/10.1097\/00001813-199803000-00001.","journal-title":"Anti-Cancer Drugs"},{"issue":"3","key":"2386_CR21","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1517\/14740330902942299","volume":"8","author":"MW Saif","year":"2009","unstructured":"Saif MW, Xyla V, Makrilia N, Bliziotis I, Syrigos K. Thrombotic microangiopathy associated with gemcitabine: rare but real. Expert Opin Drug Saf. 2009;8(3):257\u201360. https:\/\/doi.org\/10.1517\/14740330902942299.","journal-title":"Expert Opin Drug Saf"},{"issue":"6","key":"2386_CR22","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s00277-007-0429-9","volume":"87","author":"D De Smet","year":"2008","unstructured":"De Smet D, Jochmans K, Neyns B. Development of thrombotic thrombocytopenic purpura after a single dose of gemcitabine. Ann Hematol. 2008;87(6):495\u20136. https:\/\/doi.org\/10.1007\/s00277-007-0429-9.","journal-title":"Ann Hematol"},{"issue":"3","key":"2386_CR23","doi-asserted-by":"publisher","first-page":"462","DOI":"10.3109\/0284186X.2010.491088","volume":"50","author":"AE Willemsen","year":"2011","unstructured":"Willemsen AE, van Herpen CM, Wesseling P, Bult P, van Laarhoven HW. Fatal thrombotic microangiopathy after a single dose of gemcitabine as fourth-line palliative treatment for metastasized ductal breast carcinoma. Acta Oncol. 2011;50(3):462\u20135. https:\/\/doi.org\/10.3109\/0284186X.2010.491088.","journal-title":"Acta Oncol"},{"issue":"4","key":"2386_CR24","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/S0272-6386(96)90468-0","volume":"28","author":"BA Young","year":"1996","unstructured":"Young BA, Marsh CL, Alpers CE, Davis CL. Cyclosporine-associated thrombotic microangiopathy\/hemolytic uremic syndrome following kidney and kidney-pancreas transplantation. Am J Kidney Dis. 1996;28(4):561\u201371. https:\/\/doi.org\/10.1016\/S0272-6386(96)90468-0.","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"2386_CR25","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/S0272-6386(12)81010-9","volume":"23","author":"LA Hochstetler","year":"1994","unstructured":"Hochstetler LA, Flanigan MJ, Lager DJ. Transplant-associated thrombotic microangiopathy: the role of IgG administration as initial therapy. Am J Kidney Dis. 1994;23(3):444\u201350. https:\/\/doi.org\/10.1016\/S0272-6386(12)81010-9.","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"2386_CR26","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1053\/ajkd.2000.17690","volume":"36","author":"PT Pham","year":"2000","unstructured":"Pham PT, Peng A, Wilkinson AH, Gritsch HA, Lassman C, Pham PC, et al. Cyclosporine and tacrolimus-associated thrombotic microangiopathy. Am J Kidney Dis. 2000;36(4):844\u201350. https:\/\/doi.org\/10.1053\/ajkd.2000.17690.","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"2386_CR27","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1097\/00007890-199902270-00009","volume":"67","author":"HM Trimarchi","year":"1999","unstructured":"Trimarchi HM, Truong LD, Brennan S, Gonzalez JM, Suki WN. FK506-associated thrombotic microangiopathy: report of two cases and review of the literature. Transplantation. 1999;67(4):539\u201344. https:\/\/doi.org\/10.1097\/00007890-199902270-00009.","journal-title":"Transplantation."}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-021-02386-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-021-02386-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-021-02386-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T07:11:53Z","timestamp":1620803513000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-021-02386-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,12]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2386"],"URL":"https:\/\/doi.org\/10.1186\/s12882-021-02386-y","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,12]]},"assertion":[{"value":"10 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the editor of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"175"}}